Pyxis Oncology Inc. (PYXS)
NASDAQ: PYXS
· Real-Time Price · USD
1.31
0.21 (19.09%)
At close: May 02, 2025, 2:08 PM
19.09% (1D)
| Bid | 1.26 |
| Market Cap | 80.68M |
| Revenue (ttm) | 16.15M |
| Net Income (ttm) | -77.33M |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -0.99 |
| Forward PE | -0.99 |
| Analyst | Buy |
| Ask | 1.35 |
| Volume | 1,004,635 |
| Avg. Volume (20D) | 579,232 |
| Open | 1.11 |
| Previous Close | 1.10 |
| Day's Range | 1.11 - 1.32 |
| 52-Week Range | 0.83 - 5.39 |
| Beta | 1.17 |
About PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol PYXS
Website https://www.pyxisoncology.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 663.36% from the latest price.
Stock Forecasts2 months ago
-5.83%
Pyxis Oncology shares are trading higher after the...
Unlock content with
Pro Subscription
5 months ago
-45.03%
Pyxis Oncology shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform.
